| ★ |  GDF2026 - Best Practices for Safety Assessment of Nitrosamines in Generic Drugs | U.S. Food and Drug Administration @us_fda | 127 | Estados Unidos | |
| 13 |  GDF2026 - Closing Remarks | U.S. Food and Drug Administration @us_fda | 595 | Estados Unidos | 92 |
| 1 |  GDF2026 - Updates on Nitrosamines/ Nitrosamine Mitigation Strategies for Pharmaceuticals | U.S. Food and Drug Administration @us_fda | 409 | Estados Unidos | 95 |
| 3 |  GDF2026 - Quality and Safety Assessment of Extractables/Leachables in Generic Drug Products | U.S. Food and Drug Administration @us_fda | 363 | Estados Unidos | 95 |
| 14 |  GDF2026 - Q&A Discussion Panel Eight | U.S. Food and Drug Administration @us_fda | 298 | Estados Unidos | 92 |
| 10 |  GDF2026 - Q&A Discussion Panel Six | U.S. Food and Drug Administration @us_fda | 292 | Estados Unidos | 93 |
| 11 |  GDF2026 - Q&A Discussion Panel Four and Day One Closing | U.S. Food and Drug Administration @us_fda | 187 | Estados Unidos | 93 |
| 19 |  GDF2026 - Overview of the FDA Product-Specific Guidance (PSG) Program | U.S. Food and Drug Administration @us_fda | 166 | Estados Unidos | 92 |
| 2 |  GDF2026 - Bioequivalence (BE) Recommendations for Bridging Pre- and Post-Mitigation Formulations | U.S. Food and Drug Administration @us_fda | 160 | Estados Unidos | 95 |
| 17 |  GDF2026 - Office of Generic Drugs (OGD) Keynote | U.S. Food and Drug Administration @us_fda | 144 | Estados Unidos | 92 |
| 20 |  GDF2026 - Regulatory Review Process for Type II Secondary DMFs | U.S. Food and Drug Administration @us_fda | 142 | Estados Unidos | 92 |
| 7 |  GDF2026 - Q&A Discussion Panel Two | U.S. Food and Drug Administration @us_fda | 136 | Estados Unidos | 93 |
| 9 |  GDF2026 - Office of Pharmaceutical Quality (OPQ) Keynote | U.S. Food and Drug Administration @us_fda | 101 | Estados Unidos | 93 |
| 4 |  GDF2026 - Complex Drug Products – Quality Considerations for Generic Oligonucleotides | U.S. Food and Drug Administration @us_fda | 86 | Estados Unidos | 93 |
| 8 |  GDF2026 - Product-Specific Guidances (PSGs) in Action – Key Lessons and Common Questions | U.S. Food and Drug Administration @us_fda | 58 | Estados Unidos | 93 |
| 6 |  GDF2026 - Standardized Principles Used to Determine Maximum Daily Dose | U.S. Food and Drug Administration @us_fda | 57 | Estados Unidos | 93 |
| 15 |  GDF2026 - Decoding PSGs for Complex Non-Oral Generics | U.S. Food and Drug Administration @us_fda | 49 | Estados Unidos | 92 |
| 5 |  GDF2026 - Using FDA’s Inactive Ingredient Database (IID): Best Practices and Considerations | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 93 |
| 16 |  GDF2026 - Common Bioequivalence (BE) Study Design Deficiencies and How to Avoid Them | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 92 |
| 18 |  GDF2026 - Factors that Can Facilitate Assessment of Type II Drug Master Files (DMFs) | U.S. Food and Drug Administration @us_fda | 43 | Estados Unidos | 92 |
| 12 |  GDF2026 - Controlled Correspondences: Minimizing Rejections, Maximizing Results | U.S. Food and Drug Administration @us_fda | 37 | Estados Unidos | 93 |